Blueprint Medicines (BPMC) Misses Q3 EPS by 5c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.96), $0.05 worse than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Worthington Industries (WOR) Tops Q1 EPS by 7c
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets